Pyxis Oncology, Inc. Marketable Securities, Unrealized Gain (Loss)
Pyxis Oncology, Inc. (PYXS) reported Marketable Securities, Unrealized Gain (Loss) of -$4.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-13
- Pyxis Oncology, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$4.00K.
- Pyxis Oncology, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$53.00K.
- Pyxis Oncology, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was -$16.00K.
- Pyxis Oncology, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $74.00K, a 83.66% decline year-over-year.
- Pyxis Oncology, Inc. marketable securities, unrealized gain (loss) for fiscal 2025 was -$117.00K, a 209.35% decline from fiscal 2024.
- Pyxis Oncology, Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was $107.00K, a 69.84% increase from fiscal 2023.
- Pyxis Oncology, Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $63.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.00K 10-Q · filed 2026-08-13 | -$57.00K 10-Q · filed 2026-08-13 | -$73.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$53.00K 10-Q · filed 2026-08-13 | -$69.00K derived: sum of 2 quarters · filed 2026-08-13 | $5.00K derived: sum of 3 quarters · filed 2026-08-13 | -$49.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $58.00K derived: sum of 2 quarters · filed 2026-03-23 | $4.00K derived: sum of 3 quarters · filed 2026-08-13 | -$117.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $74.00K 10-Q · filed 2025-11-03 | $20.00K derived: sum of 2 quarters · filed 2026-08-13 | -$101.00K 10-Q · filed 2025-11-03 | -$282.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$54.00K 10-Q · filed 2026-08-13 | -$175.00K 10-Q · filed 2026-08-13 | -$356.00K derived: sum of 3 quarters · filed 2026-08-13 | $97.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$121.00K 10-Q · filed 2026-08-13 | -$302.00K derived: sum of 2 quarters · filed 2026-08-13 | $151.00K derived: sum of 3 quarters · filed 2026-08-13 | $109.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2024-12-31 | -$181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $272.00K derived: sum of 2 quarters · filed 2026-03-23 | $230.00K derived: sum of 3 quarters · filed 2026-03-23 | $107.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $453.00K 10-Q · filed 2025-11-03 | $411.00K derived: sum of 2 quarters · filed 2025-11-03 | $288.00K 10-Q · filed 2025-11-03 | $456.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$42.00K 10-Q · filed 2025-08-14 | -$165.00K 10-Q · filed 2025-08-14 | $3.00K derived: sum of 3 quarters · filed 2025-08-14 | -$17.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$123.00K 10-Q · filed 2025-08-14 | $45.00K derived: sum of 2 quarters · filed 2025-08-14 | $25.00K derived: sum of 3 quarters · filed 2025-08-14 | -$756.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2023-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $148.00K derived: sum of 2 quarters · filed 2025-03-18 | -$633.00K derived: sum of 3 quarters · filed 2025-03-18 | $63.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | -$20.00K 10-Q · filed 2024-11-12 | -$801.00K derived: sum of 2 quarters · filed 2024-11-12 | -$105.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$781.00K 10-Q · filed 2024-08-14 | -$85.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $696.00K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |